Literature DB >> 8023650

Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation--a brief review of recent literature.

K Shibata1, Y Shimamoto, K Suga, M Sano, M Matsuzaki, M Yamaguchi.   

Abstract

Essential thrombocythemia (ET), one of the chronic myeloproliferative disorders, is a clonal disorder of multipotent stem cells. Although most patients with ET have a prolonged benign course, a minority of patients may develop a blastic crisis similar to chronic myelogenous leukemia (CML). A case of ET terminating in blastic crisis 8 years after the initial diagnosis is presented. The blast cells were cytochemically and immunophenotypically consistent with the acute myelogenous leukemia with minimal myeloid differentiation subtype of the FAB classification. From the review of the literature on blastic transformation of ET, acute leukemia with an M4 or M7 phenotype occurred more frequently. In addition, three valuable factors to predict the leukemic transformation of ET appear to be karyotypic abnormalities, such as involvement of chromosome 21, previous therapies with a mutagenic potential, and the capability of bone marrow cells to form in vitro spontaneous colonies as in CML.

Entities:  

Mesh:

Year:  1994        PMID: 8023650     DOI: 10.1159/000204260

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  6 in total

Review 1.  Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.

Authors:  Syed J Noor; Wei Tan; Gregory E Wilding; Laurie A Ford; Maurice Barcos; Sheila N J Sait; Annemarie W Block; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Leuk Res       Date:  2010-08-19       Impact factor: 3.156

Review 2.  What is the standard treatment in essential thrombocythemia.

Authors:  Tiziano Barbui
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Multiple granulocytic sarcomas in essential thrombocythemia.

Authors:  Yasuhiro Tanaka; Yuya Nagai; Minako Mori; Haruyuki Fujita; Katsuhiro Togami; Masayuki Kurata; Akiko Matsushita; Akinori Maeda; Kenichi Nagai; Kyoko Tanaka; Takayuki Takahashi
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

Review 4.  Essential thrombocythemia.

Authors:  Jean B Brière
Journal:  Orphanet J Rare Dis       Date:  2007-01-08       Impact factor: 4.123

5.  Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.

Authors:  Cristina Santoro; Isabella Sperduti; Roberto Latagliata; Erminia Baldacci; Barbara Anaclerico; Giuseppe Avvisati; Massimo Breccia; Francesco Buccisano; Michele Cedrone; Giuseppe Cimino; Cinzia De Gregoris; Marianna De Muro; Ambra Di Veroli; Sabrina Leonetti Crescenzi; Marco Montanaro; Enrico Montefusco; Raffaele Porrini; Angela Rago; Antonio Spadea; Francesca Spirito; Nicoletta Villivà; Alesssandro Andriani; Giuliana Alimena; Maria Gabriella Mazzucconi
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

6.  Secondary Acute Myeloid Leukemia in a One-Year-Old Girl Diagnosed with JAK2-V617F Mutation Positive Myeloproliferative Neoplasm.

Authors:  Gary M Woods; Rajinder P S Bajwa; Samir B Kahwash; Terri Guinipero
Journal:  Case Rep Med       Date:  2014-03-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.